Autres langues Sanofi

Actions

SAN

FR0000120578

Produits pharmaceutiques

Marché Fermé - Euronext Paris 17:55:00 14/09/2026			Varia. 5j.	Varia. 1 janv.
75,43 ^EUR	+2,96%		-1,09%	-8,81%

14/09	Gueule de bois du lundi à Paris, l'IA au tapis
14/09	Clôture contrastée pour les bourses européennes lundi ; les taux de la BCE pourraient augmenter face à l'inflation énergétique	MT

Autres langues

14/09	European Stocks Close Mixed in Monday Trading; ECB Rates Could Rise as Energy Costs Fuel Inflation
14/09	Cheplapharm aus Greifswald und Sanofi vor Milliarden-Deal
14/09	Französischer Pharmariese Sanofi steigt bei deutscher Cheplapharm ein
14/09	Sanofi beteiligt sich an deutscher Cheplapharm
14/09	Sanofi to Acquire 26.4% Stake in Cheplapharm
14/09	Sanofi to Take Stake in Cheplapharm in Swap for Drug Portfolio, Manufacturing Sites
14/09	Sanofi Plans Strategic Partnership to Transfer Mature Medicines, Sites to Cheplapharm
14/09	Sanofi and Cheplapharm to create new strategic partnership in mature medicines
09/09	RBC Launches Sanofi Coverage at Sector Perform Amid Management Turnaround, 'Light' Near-term Catalysts
09/09	EU approves €400 million of German aid for Sanofi insulin factory
09/09	MORNING BRIEFING - Deutschland/Europa
08/09	Börsen treten auf der Stelle - Novartis brechen ein
08/09	AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups
08/09	EU genehmigt Millionen für Sanofi - Insulinfabrik in Hessen
07/09	Can A Dominant Firm’s Communications Strategy Amount To Exclusionary Conduct?
04/09	Europa todavía esconde "gangas" : cinco acciones con más de un 30% de potencial
02/09	Owkin signs AI drug discovery deal with Boehringer for cancer, immunology
01/09	Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
01/09	Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
01/09	Novartis-Aktie steigt nach MS-Studienerfolg - Rückschlag bei Zelltherapie
01/09	Novartis MS pill beats older drug in trials, boosts pipeline hopes
01/09	Novartis-Arznei erreicht gegen Multiple Sklerose in Klinik primäre Ziele
01/09	Novartis Drug Meets Key Goal in Late-Stage Multiple Sclerosis Trials
31/08	Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says